Free internal mammary artery grafts were placed in 156 patients (1971 to 1985). Preoperative clinical and angiographic variables were similar to those of other series of isolated coronary bypass grafts. Of 244 total internal mammary artery grafts, 166 were in the aorta-coronary position and were performed mainly because of unsuitable saphenous veins or to gain additional graft length. One patient (0.6%) died during hospitalization. Perioperative complications included respiratory dysfunction in 16 (10.3%), reoperation for bleeding in 13 (8.0%), stroke in four (2.6%), myocardial infarction in three (1.9%), and wound complications in two (1.3%). Morbidity occurred significantly more often in the 1971 to 1975 period. Subsequently, eight (7%) had reoperation (6 to 158 months; mean 99 months). After a 98 month mean follow-up, the 10 year actuarial survival rate (including all causes of death) was 73.3%. Of 40 free grafts restudied within 18 months of operation, 31 (77%) were patent. The higher rate of early closure is attributed to technical problems early in our experience, especially construction of the aortic anastomosis. However, 32 of 35 (91%) free grafts studied after more than 18 months (mean 94 months) were open. Fifty of 58 (86%) free internal mammary artery grafts placed to the anterior descending coronary artery, seven of nine (78%) to the circumflex, and six of eight (75.0%) to the right coronary artery were patent. Sequential catheterization showed that of 24 free grafts open at 9 months, 24 remained patent at 80 months; when six of these were restudied at 93 months (third catheterization) and two (fourth catheterization) at 125 months, all were patent. These late studies of free internal mammary artery grafts showed no evidence of graft atherosclerosis. Free internal mammary artery grafts, like in situ internal mammary artery grafts, appear to have relative immunity from atherosclerosis. These findings expand the versatility of internal mammary artery grafting and justify wider use of free internal mammary artery grafts.
Download full-text PDF |
Source |
---|
Plast Reconstr Surg
December 2024
Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea.
Background: Despite the recent steep rise in the use of prepectoral direct-to-implant (DTI) breast reconstruction, concerns remain regarding the potentially risk of complications, resulting in the selective application of the technique; however, the selection process was empirically based on the operator's decision. Using patient and operation-related factors, this study aimed to develop a nomogram for predicting postoperative complications following prepectoral DTI reconstruction.
Methods: Between August 2019 and March 2023, immediate prepectoral DTI was performed for all patients deemed suitable for one-stage implant-based reconstruction.
Noise Health
January 2025
Department of Geriatric Health Internal Medicine, Qingdao Municipal Hospital, Qingdao 266000, China.
Objective: Evaluate the effect of white noise intervention on sleep quality and immunological indicators of patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).
Methods: From January 2020 to December 2022, 104 newly diagnosed female patients (the number of people who met the inclusion criteria) with breast cancer who were confirmed to be preoperative NAC by puncture pathology were selected for a randomised single-blind trial. The patients were randomly divided into an observation group and a control group, with 52 cases in each group.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
PLoS One
January 2025
Tranzo, Scientific Center for Care and Wellbeing, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands.
Objective: An increasing number of people resumes life after cancer treatment. Although the (long-term) side-effects of cancer and its treatment can be significant, less is known about the impact on cancer survivors' participation in daily life. The aim of this study was to explore the common experiences of cancer survivors in resuming life after treatment.
View Article and Find Full Text PDFPLoS One
January 2025
Information School, The Wave, The University of Sheffield, Sheffield, United Kingdom.
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate the expression level of the target genes in the cell. Breast cancer is responsible for the majority of cancer-related deaths among women globally. It has been proven that deregulated miRNAs may play an essential role in the progression of breast cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!